Global Vulvovaginal Candidiasis Treatment Market Size study, by Drug Class (Fluconazole, Clotrimazole), Disease Type (Uncomplicated, Complicated VVC), Route of Administration (Oral, Topical), Type (Prescription, OTC), Distribution Channel and Regional Forecasts 2022-2032
Global Vulvovaginal Candidiasis Treatment Market is valued approximately at USD 1.0 billion in 2023 and is anticipated to grow with a moderate yet promising compound annual growth rate of more than 4.50% over the forecast period 2024-2032. Vulvovaginal candidiasis (VVC), commonly known as a yeast infection, is a prevalent mucosal fungal infection in women worldwide. It stems from the overgrowth of Candida species, particularly Candida albicans. Although generally non-life-threatening, its recurrent and chronic nature substantially affects quality of life and healthcare resource utilization. The market for VVC treatments is seeing a gradual evolution, driven by enhanced clinical awareness, development of antifungal agents with improved resistance profiles, and a growing demand for effective over-the-counter (OTC) and prescription-based therapies tailored to individual needs.
The rise in risk factors such as diabetes, antibiotic overuse, contraceptive usage, and immunosuppressive conditions has fueled a sustained incidence of both uncomplicated and complicated VVC cases. Pharmaceutical manufacturers are responding to this shift by introducing reformulated drug classes and novel routes of administration that ensure superior efficacy with minimal systemic exposure. In particular, topical antifungals continue to maintain a strong foothold in the market, although oral agents like fluconazole are increasingly preferred for recurrent infections due to convenience and patient adherence. Additionally, an uptick in self-diagnosis and treatment, aided by e-pharmacy growth, is contributing to increased product accessibility and market expansion across both developed and emerging economies.
However, the landscape is not without challenges. Antifungal resistance, particularly to azole-based therapies, continues to hinder treatment outcomes and necessitates the pursuit of new therapeutic classes. Furthermore, the limited pipeline of novel antifungals, coupled with diagnostic complexities and underreporting in certain demographics, dampens the speed of market innovation. On the bright side, regulatory agencies are gradually easing approval pathways for non-prescription antifungal products, while healthcare professionals advocate combination therapies and patient-centric treatment approaches to curb recurrence rates. Digital health interventions and awareness programs are also playing a pivotal role in improving early detection and timely intervention, particularly in remote and underserved communities.
The market is becoming increasingly competitive as leading companies adopt differentiation strategies via branding, formulation enhancements, and cross-channel distribution. Several players are investing in patient education, mobile diagnostics, and teleconsultation platforms to extend reach and reduce stigma surrounding candidiasis-related conditions. With the dual presence of generic and branded solutions, companies are leveraging partnerships with retail chains and hospital networks to widen their consumer base. Innovation in intravaginal delivery systems, combination formulations, and resistance-bypassing compounds are likely to offer new growth avenues, especially in countries grappling with high recurrence burdens and antimicrobial misuse.
Regionally, North America dominates the global vulvovaginal candidiasis treatment market due to high awareness levels, well-established healthcare infrastructure, and the presence of major market players. The U.S. has shown particular leadership in advancing clinical guidelines and facilitating quicker market entry for new treatments. Europe is also a significant contributor, with countries such as Germany, France, and the UK implementing national-level screening and women's health initiatives. Meanwhile, Asia Pacific is projected to witness the fastest growth, bolstered by rising healthcare spending, growing female population awareness, and improving access to antifungal drugs in nations like China, India, and Southeast Asia. Latin America and the Middle East & Africa are catching up as awareness programs, subsidized drug access, and mobile clinics gain momentum.
Major market player included in this report are:
By Drug Class
North America
The rise in risk factors such as diabetes, antibiotic overuse, contraceptive usage, and immunosuppressive conditions has fueled a sustained incidence of both uncomplicated and complicated VVC cases. Pharmaceutical manufacturers are responding to this shift by introducing reformulated drug classes and novel routes of administration that ensure superior efficacy with minimal systemic exposure. In particular, topical antifungals continue to maintain a strong foothold in the market, although oral agents like fluconazole are increasingly preferred for recurrent infections due to convenience and patient adherence. Additionally, an uptick in self-diagnosis and treatment, aided by e-pharmacy growth, is contributing to increased product accessibility and market expansion across both developed and emerging economies.
However, the landscape is not without challenges. Antifungal resistance, particularly to azole-based therapies, continues to hinder treatment outcomes and necessitates the pursuit of new therapeutic classes. Furthermore, the limited pipeline of novel antifungals, coupled with diagnostic complexities and underreporting in certain demographics, dampens the speed of market innovation. On the bright side, regulatory agencies are gradually easing approval pathways for non-prescription antifungal products, while healthcare professionals advocate combination therapies and patient-centric treatment approaches to curb recurrence rates. Digital health interventions and awareness programs are also playing a pivotal role in improving early detection and timely intervention, particularly in remote and underserved communities.
The market is becoming increasingly competitive as leading companies adopt differentiation strategies via branding, formulation enhancements, and cross-channel distribution. Several players are investing in patient education, mobile diagnostics, and teleconsultation platforms to extend reach and reduce stigma surrounding candidiasis-related conditions. With the dual presence of generic and branded solutions, companies are leveraging partnerships with retail chains and hospital networks to widen their consumer base. Innovation in intravaginal delivery systems, combination formulations, and resistance-bypassing compounds are likely to offer new growth avenues, especially in countries grappling with high recurrence burdens and antimicrobial misuse.
Regionally, North America dominates the global vulvovaginal candidiasis treatment market due to high awareness levels, well-established healthcare infrastructure, and the presence of major market players. The U.S. has shown particular leadership in advancing clinical guidelines and facilitating quicker market entry for new treatments. Europe is also a significant contributor, with countries such as Germany, France, and the UK implementing national-level screening and women's health initiatives. Meanwhile, Asia Pacific is projected to witness the fastest growth, bolstered by rising healthcare spending, growing female population awareness, and improving access to antifungal drugs in nations like China, India, and Southeast Asia. Latin America and the Middle East & Africa are catching up as awareness programs, subsidized drug access, and mobile clinics gain momentum.
Major market player included in this report are:
- Pfizer Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Mycovia Pharmaceuticals
- GlaxoSmithKline plc
- Perrigo Company plc
- Lupin Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Cadila Healthcare Ltd.
- Astellas Pharma Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Mylan N.V.
- Scynexis, Inc.
By Drug Class
- Fluconazole
- Clotrimazole
- Uncomplicated VVC
- Complicated VVC
- Oral
- Topical
- Prescription
- Over-the-Counter (OTC)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Brazil
- Mexico
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
- Pfizer Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Mycovia Pharmaceuticals
- GlaxoSmithKline plc
- Perrigo Company plc
- Lupin Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Cadila Healthcare Ltd.
- Astellas Pharma Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Mylan N.V.
- Scynexis, Inc.
CHAPTER 1. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET EXECUTIVE SUMMARY
1.1. Global Vulvovaginal Candidiasis Treatment Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Disease Type
1.3.3. By Route of Administration
1.3.4. By Type
1.3.5. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Risk Factors (Diabetes, Antibiotic Overuse)
3.1.2. Demand for Convenient, Patient-Centric Therapies
3.1.3. Growth of E-Pharmacy and Self-Diagnosis Trends
3.2. Market Challenges
3.2.1. Antifungal Resistance and Limited Novel Pipelines
3.2.2. Diagnostic Complexities and Underreporting
3.3. Market Opportunities
3.3.1. Regulatory Easing for OTC Antifungals
3.3.2. Digital Health Interventions & Teleconsultation
3.3.3. Innovative Intravaginal Delivery Systems
CHAPTER 4. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Adaptation of Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY DRUG CLASS (2022–2032)
5.1. Segment Dashboard
5.2. Fluconazole: Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.3. Clotrimazole: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 6. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY DISEASE TYPE (2022–2032)
6.1. Segment Dashboard
6.2. Uncomplicated VVC: Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.3. Complicated VVC: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 7. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)
7.1. Segment Dashboard
7.2. Oral: Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.3. Topical: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 8. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY TYPE (2022–2032)
8.1. Segment Dashboard
8.2. Prescription: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.3. Over-the-Counter (OTC): Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 9. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)
9.1. Segment Dashboard
9.2. Hospital Pharmacies: Revenue Trend Analysis, 2022 & 2032 (USD Million)
9.3. Retail Pharmacies: Revenue Trend Analysis, 2022 & 2032 (USD Million)
9.4. Online Pharmacies: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 10. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY REGION (2022–2032)
10.1. North America Market
10.1.1. U.S. Market
10.1.2. Canada Market
10.2. Europe Market
10.2.1. UK Market
10.2.2. Germany Market
10.2.3. France Market
10.2.4. Spain Market
10.2.5. Italy Market
10.2.6. Rest of Europe Market
10.3. Asia Pacific Market
10.3.1. China Market
10.3.2. India Market
10.3.3. Japan Market
10.3.4. Australia Market
10.3.5. South Korea Market
10.3.6. Rest of Asia Pacific Market
10.4. Latin America Market
10.4.1. Brazil Market
10.4.2. Mexico Market
10.5. Middle East & Africa Market
10.5.1. Saudi Arabia Market
10.5.2. South Africa Market
10.5.3. Rest of Middle East & Africa Market
CHAPTER 11. COMPETITIVE INTELLIGENCE
11.1. Key Company SWOT Analysis
11.1.1. Pfizer Inc.
11.1.2. Bayer AG
11.1.3. Novartis AG
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Pfizer Inc.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Sanofi S.A.
11.3.3. Mycovia Pharmaceuticals
11.3.4. GlaxoSmithKline plc
11.3.5. Perrigo Company plc
11.3.6. Lupin Pharmaceuticals, Inc.
11.3.7. Teva Pharmaceutical Industries Ltd.
11.3.8. Cadila Healthcare Ltd.
11.3.9. Astellas Pharma Inc.
11.3.10. Sun Pharmaceutical Industries Ltd.
11.3.11. Cipla Inc.
11.3.12. Mylan N.V.
11.3.13. Scynexis, Inc.
CHAPTER 12. RESEARCH PROCESS
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
1.1. Global Vulvovaginal Candidiasis Treatment Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Disease Type
1.3.3. By Route of Administration
1.3.4. By Type
1.3.5. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Risk Factors (Diabetes, Antibiotic Overuse)
3.1.2. Demand for Convenient, Patient-Centric Therapies
3.1.3. Growth of E-Pharmacy and Self-Diagnosis Trends
3.2. Market Challenges
3.2.1. Antifungal Resistance and Limited Novel Pipelines
3.2.2. Diagnostic Complexities and Underreporting
3.3. Market Opportunities
3.3.1. Regulatory Easing for OTC Antifungals
3.3.2. Digital Health Interventions & Teleconsultation
3.3.3. Innovative Intravaginal Delivery Systems
CHAPTER 4. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Adaptation of Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY DRUG CLASS (2022–2032)
5.1. Segment Dashboard
5.2. Fluconazole: Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.3. Clotrimazole: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 6. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY DISEASE TYPE (2022–2032)
6.1. Segment Dashboard
6.2. Uncomplicated VVC: Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.3. Complicated VVC: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 7. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)
7.1. Segment Dashboard
7.2. Oral: Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.3. Topical: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 8. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY TYPE (2022–2032)
8.1. Segment Dashboard
8.2. Prescription: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.3. Over-the-Counter (OTC): Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 9. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)
9.1. Segment Dashboard
9.2. Hospital Pharmacies: Revenue Trend Analysis, 2022 & 2032 (USD Million)
9.3. Retail Pharmacies: Revenue Trend Analysis, 2022 & 2032 (USD Million)
9.4. Online Pharmacies: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 10. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SIZE & FORECASTS BY REGION (2022–2032)
10.1. North America Market
10.1.1. U.S. Market
10.1.2. Canada Market
10.2. Europe Market
10.2.1. UK Market
10.2.2. Germany Market
10.2.3. France Market
10.2.4. Spain Market
10.2.5. Italy Market
10.2.6. Rest of Europe Market
10.3. Asia Pacific Market
10.3.1. China Market
10.3.2. India Market
10.3.3. Japan Market
10.3.4. Australia Market
10.3.5. South Korea Market
10.3.6. Rest of Asia Pacific Market
10.4. Latin America Market
10.4.1. Brazil Market
10.4.2. Mexico Market
10.5. Middle East & Africa Market
10.5.1. Saudi Arabia Market
10.5.2. South Africa Market
10.5.3. Rest of Middle East & Africa Market
CHAPTER 11. COMPETITIVE INTELLIGENCE
11.1. Key Company SWOT Analysis
11.1.1. Pfizer Inc.
11.1.2. Bayer AG
11.1.3. Novartis AG
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Pfizer Inc.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Sanofi S.A.
11.3.3. Mycovia Pharmaceuticals
11.3.4. GlaxoSmithKline plc
11.3.5. Perrigo Company plc
11.3.6. Lupin Pharmaceuticals, Inc.
11.3.7. Teva Pharmaceutical Industries Ltd.
11.3.8. Cadila Healthcare Ltd.
11.3.9. Astellas Pharma Inc.
11.3.10. Sun Pharmaceutical Industries Ltd.
11.3.11. Cipla Inc.
11.3.12. Mylan N.V.
11.3.13. Scynexis, Inc.
CHAPTER 12. RESEARCH PROCESS
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Vulvovaginal Candidiasis Treatment market, report scope
TABLE 2. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Region 2022–2032 (USD Million)
TABLE 3. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Drug Class 2022–2032 (USD Million)
TABLE 4. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Disease Type 2022–2032 (USD Million)
TABLE 5. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Route of Administration 2022–2032 (USD Million)
TABLE 6. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Type 2022–2032 (USD Million)
TABLE 7. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Distribution Channel 2022–2032 (USD Million)
TABLE 8. Global Vulvovaginal Candidiasis Treatment market by segment, estimates & forecasts, 2022–2032 (USD Million)
TABLE 9. U.S. Vulvovaginal Candidiasis Treatment market estimates & forecasts, 2022–2032 (USD Million)
TABLE 10. U.S. market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 11. Canada market estimates & forecasts, 2022–2032 (USD Million)
TABLE 12. Canada market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 13. UK market estimates & forecasts, 2022–2032 (USD Million)
TABLE 14. Germany market estimates & forecasts, 2022–2032 (USD Million)
TABLE 15. France market estimates & forecasts, 2022–2032 (USD Million)
TABLE 16. Spain market estimates & forecasts, 2022–2032 (USD Million)
TABLE 17. Italy market estimates & forecasts, 2022–2032 (USD Million)
TABLE 18. Asia Pacific market estimates & forecasts, 2022–2032 (USD Million)
TABLE 19. Latin America market estimates & forecasts, 2022–2032 (USD Million)
TABLE 20. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Million)
TABLE 1. Global Vulvovaginal Candidiasis Treatment market, report scope
TABLE 2. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Region 2022–2032 (USD Million)
TABLE 3. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Drug Class 2022–2032 (USD Million)
TABLE 4. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Disease Type 2022–2032 (USD Million)
TABLE 5. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Route of Administration 2022–2032 (USD Million)
TABLE 6. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Type 2022–2032 (USD Million)
TABLE 7. Global Vulvovaginal Candidiasis Treatment market estimates & forecasts by Distribution Channel 2022–2032 (USD Million)
TABLE 8. Global Vulvovaginal Candidiasis Treatment market by segment, estimates & forecasts, 2022–2032 (USD Million)
TABLE 9. U.S. Vulvovaginal Candidiasis Treatment market estimates & forecasts, 2022–2032 (USD Million)
TABLE 10. U.S. market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 11. Canada market estimates & forecasts, 2022–2032 (USD Million)
TABLE 12. Canada market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 13. UK market estimates & forecasts, 2022–2032 (USD Million)
TABLE 14. Germany market estimates & forecasts, 2022–2032 (USD Million)
TABLE 15. France market estimates & forecasts, 2022–2032 (USD Million)
TABLE 16. Spain market estimates & forecasts, 2022–2032 (USD Million)
TABLE 17. Italy market estimates & forecasts, 2022–2032 (USD Million)
TABLE 18. Asia Pacific market estimates & forecasts, 2022–2032 (USD Million)
TABLE 19. Latin America market estimates & forecasts, 2022–2032 (USD Million)
TABLE 20. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Million)
LIST OF FIGURES
FIG 1. Global Vulvovaginal Candidiasis Treatment market, research methodology
FIG 2. Global market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global market, key trends 2023
FIG 5. Global market, growth prospects 2022–2032
FIG 6. Porter’s Five Forces model
FIG 7. PESTEL analysis
FIG 8. Value chain analysis
FIG 9. Market by Drug Class, 2022 & 2032 (USD Million)
FIG 10. Market by Disease Type, 2022 & 2032 (USD Million)
FIG 11. Market by Route of Administration, 2022 & 2032 (USD Million)
FIG 12. Market by Type, 2022 & 2032 (USD Million)
FIG 13. Market by Distribution Channel, 2022 & 2032 (USD Million)
FIG 14. Regional snapshot 2022 & 2032
FIG 15. North America market 2022 & 2032 (USD Million)
FIG 16. Europe market 2022 & 2032 (USD Million)
FIG 17. Asia Pacific market 2022 & 2032 (USD Million)
FIG 18. Latin America market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa market 2022 & 2032 (USD Million)
FIG 20. Antifungal resistance & novel therapies trends (2023)
FIG 1. Global Vulvovaginal Candidiasis Treatment market, research methodology
FIG 2. Global market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global market, key trends 2023
FIG 5. Global market, growth prospects 2022–2032
FIG 6. Porter’s Five Forces model
FIG 7. PESTEL analysis
FIG 8. Value chain analysis
FIG 9. Market by Drug Class, 2022 & 2032 (USD Million)
FIG 10. Market by Disease Type, 2022 & 2032 (USD Million)
FIG 11. Market by Route of Administration, 2022 & 2032 (USD Million)
FIG 12. Market by Type, 2022 & 2032 (USD Million)
FIG 13. Market by Distribution Channel, 2022 & 2032 (USD Million)
FIG 14. Regional snapshot 2022 & 2032
FIG 15. North America market 2022 & 2032 (USD Million)
FIG 16. Europe market 2022 & 2032 (USD Million)
FIG 17. Asia Pacific market 2022 & 2032 (USD Million)
FIG 18. Latin America market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa market 2022 & 2032 (USD Million)
FIG 20. Antifungal resistance & novel therapies trends (2023)
